Antibodies to Tie1 ectodomain
View Patent ↗Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.
1. An isolated protein comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the protein binds to Tie1 ectodomain and
(A) the HC immunoglobulin variable domain sequence comprises:
i) a HC CDR1 that comprises the amino acid sequence (AGSIMRH)-Y-(GVMK)-M-(GSVMFH) (SEQ ID NO:118);
ii) a HC CDR2 that comprises the amino acid sequence (GSV)-I-(SY)-P-S-G-G-(WNQ)-T-(GY) (SEQ ID NO: 160);
iii) a HC CDR3 that comprises the amino acid sequence A-P-R-G-Y-S-Y-G-Y-Y-Y (amino acids 99-109 of SEQ ID NO:114); and
B) the LC immunoglobulin variable domain sequence comprises:
i) a LC CDR1 that comprises the amino acid sequence R-A-S-(REQ)-(GSTRN)-(IV)-(GSTIRN)-(STIRH)-X1-(SYWNH)-(LV)-(ASN) (SEQ ID NO:132), wherein X1 is serine or absent;
ii) a LC CDR2 that comprises the amino acid sequence (AGTKDEH)-A-S-(STN)-(LR)-(AVEQ)-(ST) (SEQ ID NO: 136); and
iii) a LC CDR3 that comprises the amino acid sequence Q-Q-(SYFR)-(GSYN)-S-(STYW)-(RP)-(LWRH)-(TIY) (SEQ ID NO: 161).
2. The isolated protein of claim 1 ,
wherein the HC immunoglobulin variable domain comprises a sequence that is at least 85% identical to the HC immunoglobulin variable domain of SEQ ID NO: 114 or
wherein the HC immunoglobulin variable domain comprises residues 1-141 of SEQ ID NO:701.
3. The protein of claim 1 that inhibits tube formation by HUVEC cells in vitro.
4. The protein of claim 1 , wherein the protein binds to a Tie1 ectodomain and competes with an antibody for binding to Tie1, wherein the antibody HC variable domain comprises SEQ ID NO:114 or residues 1-141 of SEQ ID NO:701, and the antibody LC variable domain comprises SEQ ID NO:116 or SEQ ID NO:159.
5. A pharmaceutical composition comprising a protein of claim 1 and a pharmaceutically acceptable carrier.
6. The isolated protein of claim 1 ,
wherein the HC immunoglobulin variable domain comprises a sequence that is encoded by a nucleic acid that hybridizes with high stringency to a nucleic acid encoding the antibody HC immunoglobulin variable domain of SEQ ID NO:114 or
wherein the HC immunoglobulin variable domain comprises residues 1-141 of SEQ ID NO:701.
7. The isolated protein of claim 1 ,
wherein the LC immunoglobulin variable domain comprises a sequence that is at least 85% identical to the antibody LC immunoglobulin variable domain of SEQ ID NO:116 or
wherein the LC immunoglobulin variable domain comprises SEQ ID NO:159.
8. The isolated protein of claim 1 ,
wherein the HC and LC immunoglobulin variable domain sequences are at least 85% identical to the antibody HC and LC immunoglobulin variable domains of SEQ ID NOS:114 and 116, respectively, or
wherein the HC and LC immunoglobulin variable domain sequences comprise residues 1-141 of SEQ ID NO:701 and SEQ ID NO:159, respectively.
9. The isolated protein of claim 1 , wherein the protein comprises the HC immunoglobulin variable domain of SEQ ID NO:114.
10. The isolated protein of claim 1 , wherein the protein comprises the LC immunoglobulin variable domain of SEQ ID NO:116.
11. The isolated protein of claim 1 , wherein the protein comprises the HC and LC immunoglobulin variable domains of the antibody of SEQ ID NOS:114 and 116, respectively.
12. The isolated protein of claim 1 , wherein the protein comprises the HC immunoglobulin variable domain of residues 1-141 of SEQ ID NO:701.
13. The isolated protein of claim 1 , wherein the protein comprises the LC immunoglobulin variable domain of SEQ ID NO:159.
14. The isolated protein of claim 1 , wherein the protein comprises the HC and LC immunoglobulin variable domains of the antibody of residues 1-141 of SEQ ID NO:701 and SEQ ID NO:159, respectively.
15. The isolated protein of claim 1 , wherein the protein comprises the HC of SEQ ID NO:701.
16. The isolated protein of claim 1 , wherein the protein comprises the LC of SEQ ID NO:700.
17. A method of decreasing angiogenesis in a subject, the method comprising administering to a subject an effective amount of the isolated protein of claim 1 , wherein the subject has a disorder selected from the group consisting of a neoplastic disorder, a metastatic cancer and an angiogenesis-dependent cancer or tumor.
18. The method of claim 17 , wherein the isolated protein is an antibody that binds to the extracellular domain of human Tie1.
19. The method of claim 17 , wherein the isolated protein is administered for a time effective to decrease angiogenesis in the subject.
20. A method of treating an angiogenesis-related disorder in a subject by decreasing angiogenesis in the subject, the method comprising providing a first therapy that comprises administering to the subject the isolated protein of claim 1 in combination with a second therapy, wherein the angiogenesis-related disorder is a disorder selected from the group consisting of a neoplastic disorder, a metastatic cancer and an angiogenesis-dependent cancer or tumor.
21. The method of claim 20 , wherein the second therapy is an anti-cancer therapy and the subject is diagnosed with cancer.
22. The method of claim 21 , wherein the anti-cancer therapy comprises administration of an agent that antagonizes signaling through a VEGF pathway.
23. A method for detecting the presence of a Tie1 protein in a sample in vitro, the method comprising:
(i) contacting the sample with the isolated protein of claim 1 in vitro, under conditions that allow interaction of the isolated protein and the Tie1 protein to occur; and
(ii) detecting formation of a complex between the Tie-binding protein and the sample, thereby detecting the presence of a Tie1 protein in a sample in vitro.
24. A method for detecting and or/localizing a Tie1 protein in a subject in vivo, the method comprising:
(i) administering to a subject the isolated protein of claim 1 , under conditions that allow interaction of the isolated protein and the Tie1 protein to occur; and
(ii) detecting formation of a complex between the isolated protein and the Tie1 protein or detecting distribution of the isolated protein in at least one location in the subject.
25. The method of claim 24 , wherein the subject is a human.
26. The method of claim 17 , wherein the angiogenesis-dependent cancer or tumor is a renal cancer.
27. The method of claim 17 , wherein the angiogenesis-dependent cancer or tumor is a hepatic cancer or a hepatoma.
28. The method of claim 20 , wherein the angiogenesis-dependent cancer or tumor is a renal cancer.
29. The method of claim 20 , wherein the angiogenesis-dependent cancer or tumor is a hepatic cancer or a hepatoma.